International Medical Cannabis Pharmaceutical Company

Latest News

Jan 12, 2022

Apollon Formularies appoints long-time advisor and shareholder as non-exec director
View Article

Jan 10, 2022

Apollon Formularies inks agreements with 'over a dozen' cannabis growers in Jamaica
View Article

Jan 06, 2022

Apollon Formularies gets green light for Jamaica medical cannabis licence renewal
View Article

Read the more news on Apollon Formularies >

Our Expertise

Cancer

Apollon medical cannabis formulations kill breast cancer cells at a rate of nearly 100% as demonstrated by recent third-party independent pre-clinical 3D cell culture laboratory data at BIOENSIS laboratories.

Chronic Pain

The National Academy of Science 2017 Report cited conclusive or substantial evidence that cannabis and/or cannabinoids are effective for the treatment of chronic pain in adults.

Palliative Care

The last days and hours of a person’s life can be associated with immense physical as well as emotional suffering. Medical cannabis may be of value for a number of conditions related to palliative care including but not limited to pain, nausea and vomiting, depression, anxiety and appetite stimulation.

THC

THC is known for its psychoactive properties, but the chemical has proven to be an ideal treatment for pain. High THC formulations can also be especially useful for patients in palliative care and cancer treatments. For other medical conditions that require extreme potency, large quantities of THC can be an effective tool for providing comfort and relief under the supervision of a licensed physician.

Schedule Appointment

Schedule an appointment with us to discuss either:
Physician Consultation, Share Dealing Enquiries, General Enquiries or legal wholesale purchase of Apollon Products

Apollon Negril Facility

The Apollon Negril Facility has been utilised since 2015 to provide in-patient and out-patient medical cannabis treatment for use by patients needing access to prescribed medical cannabis. Apollon has treated in excess of 400 patients in the last 24 months at this facility.